ULTRESA + PANCREAZE + CREON + ZENPEP + other non-sponsor pancreatic enzyme replacement therapy + PERTZYE
Pre-clinicalTerminated 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fibrosing Colonopathy
Conditions
Fibrosing Colonopathy
Trial Timeline
Jul 31, 2012 → Apr 8, 2020
NCT ID
NCT01652157About ULTRESA + PANCREAZE + CREON + ZENPEP + other non-sponsor pancreatic enzyme replacement therapy + PERTZYE
ULTRESA + PANCREAZE + CREON + ZENPEP + other non-sponsor pancreatic enzyme replacement therapy + PERTZYE is a pre-clinical stage product being developed by AbbVie for Fibrosing Colonopathy. The current trial status is terminated. This product is registered under clinical trial identifier NCT01652157. Target conditions include Fibrosing Colonopathy.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01652157 | Pre-clinical | Terminated |
Competing Products
1 competing product in Fibrosing Colonopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Baricitinib 4 MG Oral Tablet | Eli Lilly | Approved | 85 |